- Home
- AQMS vs SYBX Comparison
AQMS vs SYBX Comparison
Compare AQMS & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQMS
- SYBX
- Stock Information
- Founded
- AQMS 2014
- SYBX N/A
- Country
- AQMS United States
- SYBX United States
- Employees
- AQMS N/A
- SYBX N/A
- Industry
- AQMS Metal Fabrications
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- AQMS Industrials
- SYBX Health Care
- Exchange
- AQMS Nasdaq
- SYBX Nasdaq
- Market Cap
- AQMS 13.7M
- SYBX 11.8M
- IPO Year
- AQMS 2015
- SYBX N/A
- Fundamental
- Price
- AQMS $1.52
- SYBX $1.16
- Analyst Decision
- AQMS Strong Buy
- SYBX
- Analyst Count
- AQMS 3
- SYBX 0
- Target Price
- AQMS $21.00
- SYBX N/A
- AVG Volume (30 Days)
- AQMS 73.8K
- SYBX 13.5K
- Earning Date
- AQMS 05-14-2025
- SYBX 05-13-2025
- Dividend Yield
- AQMS N/A
- SYBX N/A
- EPS Growth
- AQMS N/A
- SYBX N/A
- EPS
- AQMS N/A
- SYBX N/A
- Revenue
- AQMS N/A
- SYBX $8,000.00
- Revenue This Year
- AQMS N/A
- SYBX N/A
- Revenue Next Year
- AQMS $550.00
- SYBX N/A
- P/E Ratio
- AQMS N/A
- SYBX N/A
- Revenue Growth
- AQMS N/A
- SYBX N/A
- 52 Week Low
- AQMS $1.33
- SYBX $0.90
- 52 Week High
- AQMS $11.40
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- AQMS 36.08
- SYBX 50.18
- Support Level
- AQMS $1.42
- SYBX $1.00
- Resistance Level
- AQMS $1.54
- SYBX $1.10
- Average True Range (ATR)
- AQMS 0.16
- SYBX 0.10
- MACD
- AQMS -0.01
- SYBX 0.01
- Stochastic Oscillator
- AQMS 11.11
- SYBX 84.64
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.